Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Jun

2010

Aquinox Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Metabolism, X - Oncology

Aquinox Pharmaceuticals (Canada) a preclinical-stage small-molecule drug company focused on cancer, immune disorders and metabolic disease, closed a $25M Series B financing. Participants include Ventures West Capital, Johnson & Johnson Development Corp., Baker Brothers Investments, BC Advantage Funds and Pfizer Venture Investments.

Apr

2010

Catabasis Pharmaceuticals, Inc.: Series A $39.6M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Inflammation, X - Metabolism, XX - MA

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Mar

2010

NGM Biopharmaceuticals, Inc.: Series B $51M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Diabetes, X - Metabolism, X - Obesity, XX - CA

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

Mar

2010

Rhythm Pharmaceuticals, Inc.: Series A $10M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Diabetes, X - GI, X - Metabolism, X - Obesity, XX - MA

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Sep

2009

aTyr Pharma, Inc.: Series C $12M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Autoimmune, X - Hematology, X - Inflammation, X - Metabolism, XX - CA

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on inflammation, autoimmune, hematopoietic and metabolic disorders, closed a $12M Series C financing. Participants include Alta Partners, Cardinal Partners and Polaris Ventures.

Jul

2009

Limerick BioPharma, Inc.: Series C $15M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Immunology, X - Metabolism, X - Pain, XX - CA

Limerick BioPharma (San Francisco, CA) a clinical-stage biopharmaceutical company focused on the modulation of cellular pumps and other transporters, closed a $15M Series C financing. Participants include OVP Venture Partners, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds.

Jul

2009

Aileron Therapeutics, Inc.: Series D $40M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Immunology, X - Inflammation, X - Metabolism, X - Oncology, XX - MA

Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.

Jun

2009

Versartis, Inc.: Series A $11M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Diabetes, X - Endocrinology, X - Growth Deficiency, X - Metabolism, XX - CA

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

May

2009

Elixir Pharmaceuticals, Inc.: Series D $12M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, XX - MA

Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

« Previous Entries

to top of page...